Overview

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Biohaven Pharmaceuticals, Inc.

Collaborator:

Biohaven Pharmaceutical Holding Company Ltd.